BVX20-CD20 antibody (Biocon/Vaccinex)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBVX20-CD20 antibody (Biocon/Vaccinex)
Drug Alias NameBVX-20BVX20-MAb
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBiocon LtdVaccinex Inc
China Registration ClassN/A

Develop Information

Active CompaniesVaccinex IncBiocon Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A